Candidate treatment for muscle wasting misses goals, GTx says

08/19/2013 | Reuters

GTx said enobosarm, its experimental drug for cancer-induced muscle wasting, failed to enhance body mass and physical function in cancer patients in two late-stage trials. The firm plans to meet with the FDA to discuss the future of the drug, which received fast-track designation this year. In one of the studies, patients gained lean body mass.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC